Two chondrosarcoma patients had responses to the death receptor ligand therapy Apo2L/TRAIL (recombinant human protein apoptosis ligand 2/TNF-related apoptosis-inducing ligand or dulanermin), with one chondrosarcoma patient remaining on therapy with sustained response for > 5 years. The gene discussed is TNFSF10; the disease is chondrosarcoma.